PURPOSE: Our aim was to evaluate the effectiveness of two different dosing regimens of human recombinant erythropoietin (rHu-EPO) for preoperative autologous blood collection in patients undergoing total hip arthroplasty (THA). METHODS: Prospective randomised trials in which erythropoietin 15,000 IU was administered intravenously twice a week or 30,000 IU once a week (total 90,000 IU) combined with ferrous II sulphate (Ferro-Gradumet 2) orally and compared with Ferro-Gradumet 2 alone. RESULTS: Although different dosing regimens of rHu-EPO administration during preoperative autologous blood donation have similar effects on the collection of two units of autologous blood, preoperative haemoglobin level and perioperative allogenic blood transfusion, a once weekly dose regimen of rHu-EPO was more convenient (although not statistically significantly) for patients. CONCLUSION: We recommend the more practical and comfortable but yet highly effective therapeutic regimen with a single weekly intravenous administration of rHu-EPO for patients scheduled for THA.
PURPOSE: Our aim was to evaluate the effectiveness of two different dosing regimens of human recombinant erythropoietin (rHu-EPO) for preoperative autologous blood collection in patients undergoing total hip arthroplasty (THA). METHODS: Prospective randomised trials in which erythropoietin 15,000 IU was administered intravenously twice a week or 30,000 IU once a week (total 90,000 IU) combined with ferrous II sulphate (Ferro-Gradumet 2) orally and compared with Ferro-Gradumet 2 alone. RESULTS: Although different dosing regimens of rHu-EPO administration during preoperative autologous blood donation have similar effects on the collection of two units of autologous blood, preoperative haemoglobin level and perioperative allogenic blood transfusion, a once weekly dose regimen of rHu-EPO was more convenient (although not statistically significantly) for patients. CONCLUSION: We recommend the more practical and comfortable but yet highly effective therapeutic regimen with a single weekly intravenous administration of rHu-EPO for patients scheduled for THA.
Authors: Nicole Casadevall; Joelle Nataf; Beatrice Viron; Amir Kolta; Jean-Jacques Kiladjian; Philippe Martin-Dupont; Patrick Michaud; Thomas Papo; Valerie Ugo; Irene Teyssandier; Bruno Varet; Patrick Mayeux Journal: N Engl J Med Date: 2002-02-14 Impact factor: 91.245
Authors: Nadia Rosencher; Hans E M Kerkkamp; G Macheras; L M Munuera; G Menichella; David M Barton; Saskia Cremers; Ivo L Abraham Journal: Transfusion Date: 2003-04 Impact factor: 3.157
Authors: Jose A Salido; Luis A Marín; Luis A Gómez; Pedro Zorrilla; Cristóbal Martínez Journal: J Bone Joint Surg Am Date: 2002-02 Impact factor: 5.284
Authors: Rohini Ramakrishnan; Wing K Cheung; Mary C Wacholtz; Neil Minton; William J Jusko Journal: J Clin Pharmacol Date: 2004-09 Impact factor: 3.126
Authors: Charles L Bennett; Stefano Luminari; Allen R Nissenson; Martin S Tallman; Stephen A Klinge; Norene McWilliams; June M McKoy; Benjamin Kim; E Allison Lyons; Steve M Trifilio; Dennis W Raisch; Andrew M Evens; Timothy M Kuzel; Glen T Schumock; Steven M Belknap; Francesco Locatelli; Jerôme Rossert; Nicole Casadevall Journal: N Engl J Med Date: 2004-09-30 Impact factor: 91.245
Authors: Nael Hawi; Daniel Oliver Kendoff; Udo Hessling; Carl Haasper; Thorsten Gehrke; Mustafa Citak Journal: Int Orthop Date: 2014-05-11 Impact factor: 3.075